Drug Approval | August 28, 2021
Japan approves AstraZeneca’s Forxiga for chronic kidney disease
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Over 13 million people in Japan suffer from chronic kidney disease and this will transform treatment options
Roche is notifying healthcare professionals and patients in the US about this withdrawal. Patients being treated with Tecentriq for PD-L1-positive mTNBC should discuss their care with their healthcare provider
In the last two years, Sai Life Sciences has made significant investments and progress in advancing its sustainability agenda as part of its organizational transformation initiative
The module offers the first preclinical laboratory information system of its kind that is fully integrated into the digital pathology workflow and provides efficient pathological studies of whole slides
As part of the PMGDisha-CoWIN integration, Mercer | Mettl has aggregated the database of 5 crore Aadhaar-authenticated and registered candidates, which is now being utilized to deliver vaccinations to the last mile populace
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis
This brings hope for patients suffering from all types of hernia, as the centre has a replenished armamentarium of technology and techniques to produce a good outcome
Caspian Debt has in principle committed up to Rs 35 crores to SAMRIDH’s commercial debt investment pool
The company plans to invest in technology, business development, product innovation, and development across India
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
Subscribe To Our Newsletter & Stay Updated
